WALTHAM, Mass. June 21, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that the U.S. Food and Drug Administration (FDA) has approved Vyleesi (bremelanotide injection), a melanocortin receptor agonist, to treat acquired,…Original Article
AMAG Pharmaceuticals Announces FDA Approval of Vyleesi (bremelanotide injection) for Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
